ALVO

Company Overview — What Does Alvotech Do?

N/A Alvotech (ALVO) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark L. PhD and employs approximately 4 people. With a market capitalization of $1.1B, ALVO is one of the notable companies in the Healthcare sector.

Alvotech (ALVO) Stock Rating — Reduce (April 2026)

As of April 2026, Alvotech receives a Reduce rating with a composite score of 30.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ALVO ranks #3,814 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Alvotech ranks #642 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALVO Stock Price and 52-Week Range

Alvotech (ALVO) currently trades at $3.62. The stock gained $0.02 (0.6%) in the most recent trading session. The 52-week high for ALVO is $11.85, which means the stock is currently trading -69.5% from its annual peak. The 52-week low is $3.45, putting the stock 4.9% above its annual trough. Recent trading volume was 174K shares, suggesting relatively thin trading activity.

Is ALVO Overvalued or Undervalued? — Valuation Analysis

Alvotech (ALVO) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 0.46x, compared to 1.66x for the average Healthcare stock.

At current multiples, Alvotech trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Alvotech Profitability — ROE, Margins, and Quality Score

Alvotech (ALVO) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -75.9% versus the sector average of -33.1%.

On a margin basis, Alvotech reports gross margins of 15.8%, compared to 71.5% for the sector. The operating margin is -25.0% (sector: -66.1%). Net profit margin stands at -40.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALVO Debt, Balance Sheet, and Financial Health

Balance sheet data for ALVO is evaluated through our stability factor. Total debt on the balance sheet is $1.18B. Cash and equivalents stand at $51M.

ALVO has a beta of 0.91, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Alvotech is 39/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Alvotech Revenue and Earnings History — Quarterly Trend

In TTM 2026, Alvotech reported revenue of $580M and earnings per share (EPS) of $-0.87. Net income for the quarter was $-232M. Gross margin was 15.8%. Operating income came in at $-145M.

In FY 2024, Alvotech reported revenue of $580M and earnings per share (EPS) of $-0.87. Net income for the quarter was $-232M. Gross margin was 15.8%. Revenue grew 523.8% year-over-year compared to FY 2023. Operating income came in at $-145M.

In FY 2023, Alvotech reported revenue of $93M and earnings per share (EPS) of $-2.43. Net income for the quarter was $-552M. Gross margin was -360.1%. Revenue grew -5.2% year-over-year compared to FY 2022. Operating income came in at $-644M.

In FY 2022, Alvotech reported revenue of $98M and earnings per share (EPS) of $-2.60. Net income for the quarter was $-514M. Gross margin was -157.3%. Revenue grew 4.5% year-over-year compared to FY 2021. Operating income came in at $-522M.

Over the past 5 quarters, Alvotech has demonstrated a growth trajectory, with revenue expanding from $94M to $580M. Investors analyzing ALVO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALVO Dividend Yield and Income Analysis

Alvotech (ALVO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALVO Momentum and Technical Analysis Profile

Alvotech (ALVO) has a momentum factor score of 32/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 18/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

ALVO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Alvotech (ALVO) ranks #642 out of 838 stocks based on the Blank Capital composite score. This places ALVO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALVO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALVO vs S&P 500 (SPY) comparison to assess how Alvotech stacks up against the broader market across all factor dimensions.

ALVO Next Earnings Date

No upcoming earnings date has been announced for Alvotech (ALVO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALVO? — Investment Thesis Summary

The quantitative profile for Alvotech suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Momentum is weak at 32/100, a headwind for near-term performance. High volatility (stability score 39/100) increases portfolio risk.

In summary, Alvotech (ALVO) earns a Reduce rating with a composite score of 30.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALVO stock.

Related Resources for ALVO Investors

Explore more research and tools: ALVO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALVO head-to-head with peers: ALVO vs AZN, ALVO vs SLGL, ALVO vs VMD.